Skip to main content
Fig. 4 | The Journal of Headache and Pain

Fig. 4

From: Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study

Fig. 4

Patient perceptionsa; a anxietyb,c; b depressed moodb,d; c sleep qualityb; d acute medication use changese,f. CM, chronic migraine; EM, episodic migraine. aChanges from baseline; 3-month baseline period before the first injection during fremanezumab treatment. bFor the changes in anxiety, depressed mood, and sleep quality, patients responded to the following questions: “Compared to the 3-month baseline period before the first injection, on a scale of 0 to 10, where 0 is ‘significantly worse’ and 10 is ‘significantly better’…” “…how much change in anxiety level did you feel while you were taking the study medicine?” “…how much change in depressed mood did you feel while you were taking the study medicine?” “…how much worse or better was your sleep quality while you were taking the study medicine compared to the 3-month baseline period before the first injection?”. cImpact of fremanezumab treatment on anxiety was only evaluated for patients with self-reported anxiety during the 3-month baseline period (n = 109). dDue to a data anomaly, the baseline depression question was re-validated among survey participants. The results here are in a sub-sample of patients with self-reported depressed mood during the baseline period (n = 68). eFor the changes in acute medication use, patients responded to the following question: “Compared to the 3-month baseline period before the first injection, on a scale of 0 to 10, where 0 is ‘significantly less’ and 10 is ‘much more,’ how much did you rely on rescue or abortive medicines that stop migraine symptoms (ex: sumatriptan, naratriptan, rizatriptan) and over-the-counter medicines while you were taking the study medicine?” fPercentages may not total 100% due to rounding. gNo difference

Back to article page